In a nutshell The study analyzed outcomes of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) for patients with non-Hodgkin lymphoma (NHL) in a resource-limited country and evaluated whether upfront AHSCT could be an effective treatment. The authors found promising outcomes of this treatment in a resource-limited...Read More
Type of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor
Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients. Some...Read More
Is R-FND and ibritumomab tiuxetan an appropriate treatment for untreated high-risk follicular lymphoma?
In a nutshell This trial was carried out to assess the effectiveness R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) followed by ibritumomab tiuxetan (YIT; Zevalin) radioimmunotherapy (RIT), and rituximab maintenance therapy in patients with untreated high-risk follicular...Read More
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...Read More
In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable). The details For B-cell NHL which has relapsed (returned) after...Read More
In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...Read More
In a nutshell This initial study looked at using CAR T cells with two targets to treat relapsed B cell non-Hodgkin lymphoma (NHL). It found that this type of immunotherapy was safe and effective, and may cause less inflammation than other types of CAR T cell treatment. Some background Chimeric antigen receptor T (CAR T) cells are a treatment for...Read More
In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...Read More
In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...Read More
In a nutshell This study looked at the quality of life for patients with advanced follicular lymphoma (FL) who were treated with obinutuzumab (Gazyva) and chemotherapy compared to those treated with rituximab (Rituxan) and chemotherapy. It found that both targeted antibody therapies improved quality of life for patients with advanced FL. Some background...Read More
Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?
In a nutshell This study examined how effective and safe a higher radiotherapy dose was for patients with non-Hodgkin lymphoma (NHL) undergoing stem cell transplantation (SCT). The authors found that patients who received a lower radiotherapy dose survived longer and had fewer side effects than the higher dose. Some background NHL is a cancer of...Read More
In a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...Read More